- •Cladribine treatment demonstrates long-term clinical benefits in terms of annual relapse rate, relapse-free status, disability progression, and NEDA-2 ratio for patients with multiple sclerosis.
- •Cladribine treatment resulted in significant decrease of annual relapse rate from 1.6 to 0.36 and 0.17 in Years 3 and 4 of treatment, respectively.
- •Disability was stable or improved in majority of the patients in Years 3 and 4.
- •NEDA-2 was achieved in 59% and 74.3% of patients in Years 3 and 4, respectively.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.Mult. Scler. 2019; 25: 1746-1753
- 2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells.Int. Immunopharmacol. 2022; 105108571
- Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.J. Neurol. 2018; 265: 1199-1209
- Cladribine tablets for relapsing-remitting multiple sclerosis: a Clinician’s review.Neurol. Ther. 2022; 11: 571-595
- A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.N. Engl. J. Med. 2010; 362: 416-426
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.Lancet Neurol. 2011; 10: 329-337
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?.Mult. Scler. Relat. Disord. 2015; 4: 329-333
- Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study.Mult. Scler. 2018; 24: 1594-1604
- Long-term disease stability assessed by the expanded disability status scale in patients treated with Cladribine tablets 3.5 mg/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies.Adv. Ther. 2021; 38: 4975-4985
- Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study.Mult. Scler. 2022; 28: 1219-1228
- Review of transporter substrate, inhibitor, and inducer characteristics of Cladribine.Clin. Pharmacokinet. 2021; 60: 1509-1535
- Real-world data as external controls: practical experience from notable marketing applications of new therapies.Ther. Innov. Regul. Sci. 2022; https://doi.org/10.1007/s43441-022-00413-0
- Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.Eur. J. Neurol. 2009; 16: 409-412
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.Lancet Neurol. 2014; 13: 257-267
- Impact of cladribine on soluble adhesion molecules in multiple sclerosis.Acta Neurol. Scand. 2010; 122: 409-413
- Single-center 8-years clinical follow-up of Cladribine-treated patients from phase 2 and 3 trials.Front. Neurol. 2020; 11: 489
- Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.Ann. Clin. Transl. Neurol. 2020; 7: 2199-2212
- Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).Ther. Adv. Neurol. Disord. 2020; 13 (1756286420922685)
- The development of Cladribine tablets for the treatment of multiple sclerosis: a comprehensive review.Drugs. 2020; 80: 1901-1928
- Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers.Ther. Adv. Neurol. Disord. 2019; 12 (1756286419854986)
- Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.Curr. Med. Res. Opin. 2021; 37: 459-464